Desmocollin 3 variant B (DSC3B) is a potential variant of the desmocollin 3 protein that is part of the desmosome cell structures, which facilitate adhesion between epithelial cells. Desmocollins, along with desmogleins, are critical for the structural integrity and function of these intercellular junctions. The gene expression of DSC3B, akin to other genes, is subject to regulation by various biochemical pathways and molecular interactions within the cell. The expression of DSC3B, when not properly regulated, has the potential to disrupt cellular adhesion and influence the behavior of epithelial cells. As a result, understanding the regulation of DSC3B gene expression is an area of significant interest, particularly in the context of cellular biology and the molecular mechanisms that govern cell-cell adhesion.
In the realm of molecular biology, several chemical compounds have been identified that can potentially inhibit the expression of genes like DSC3B. Compounds such as 5-Azacytidine and Decitabine are known to induce DNA demethylation, which can lead to the downregulation of gene expression by altering the transcriptional landscape. Histone deacetylase inhibitors, such as Vorinostat, have the ability to remodel chromatin structure, making the DNA less accessible for transcription and thereby reducing the expression of certain genes. Other compounds, including Mithramycin A and Actinomycin D, can bind directly to DNA, thereby obstructing the transcriptional machinery from accessing the gene and initiating mRNA synthesis. Moreover, molecules like Triptolide can inhibit transcription factors, leading to decreased gene expression, while compounds such as Rapamycin and Sirolimus target the mTOR signaling pathway, which plays a role in modulating protein synthesis. These chemical compounds, through their diverse mechanisms of action, present a spectrum of molecular tools that can potentially decrease the expression of DSC3B by targeting various steps and factors involved in gene expression. It is important to note that the use of these compounds is strictly for understanding the biological function and regulation of gene expression, and they serve as valuable resources in research focused on the intricate mechanisms of cellular operation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
Could demethylate DNA at the DSC3B gene promoter, leading to decreased binding of transcription machinery and subsequent downregulation of DSC3B expression. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Might bind selectively to the DSC3B gene promoter, obstructing the assembly of transcription factors and thus reducing DSC3B transcription initiation. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
Interferes with DNA replication and transcription processes, which may result in decreased DSC3B mRNA synthesis due to inhibited topoisomerase II activity or DNA intercalation. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Binds to the DNA template, hindering RNA polymerase progression along the DSC3B gene, resulting in decreased mRNA production of DSC3B. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
May interfere with specific transcription factors necessary for DSC3B expression, leading to reduced transcript levels and subsequent protein downregulation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits the mTOR pathway, which could lead to a general decrease in cap-dependent translation, including the synthesis of DSC3B. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Alters the chromatin structure around the DSC3B gene by inhibiting histone deacetylases, leading to less accessible DNA and decreased DSC3B expression. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
By hypomethylating the DSC3B gene promoter, it could decrease the expression of DSC3B through the removal of epigenetic silencing marks. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Serves as an agonist for retinoic acid receptors which can alter the transcriptional control of genes including DSC3B, potentially resulting in decreased expression levels. | ||||||
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $109.00 | 3 | |
Antagonizes mineralocorticoid receptors, which may lead to transcriptional changes in several genes, including a decrease in DSC3B expression. | ||||||